{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:10:43Z","timestamp":1793139043726,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008467","name":"Canadian Association of Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008467","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ijrobp.2022.04.006","type":"journal-article","created":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T10:03:32Z","timestamp":1649585012000},"page":"1036-1043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Acute Toxicity of Ultrahypofractionation Compared With Moderate Hypofractionation in Prostate Cancer Treatment: A Randomized Trial"],"prefix":"10.1016","volume":"113","author":[{"given":"Winkle","family":"Kwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2022.04.006_bib0001","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO, and AUA evidence-based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0002","first-page":"1314","article-title":"Controversies in prostate cancer radiotherapy: consensus development","volume":"8","author":"Lukka","year":"2001","journal-title":"Can J Urol"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2012.11324.x","article-title":"An updated prostate cancer staging nomogram (Partin tables) based on cases 2006 to 2011","volume":"111","author":"Eifler","year":"2012","journal-title":"BJUI"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0004","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0005","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.radonc.2018.02.029","article-title":"Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial","volume":"127","author":"Quon","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0006","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase II screening trials","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0007","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the expanded prostate cancer index composite short form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0008","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ijrobp.2008.11.043","article-title":"Urinary symptoms flare in 712 125I prostate brachytherapy patients: Long-term follow-up","volume":"75","author":"Keyes","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0009","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0360-3016(03)00210-4","article-title":"Urinary symptom flare following I-125 prostate brachytherapy","volume":"56","author":"Cesaretti","year":"2003","journal-title":"Int J Radiat Oncol Biol Physics"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0010","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostate hyperplasia specific health status measures in clinical research: How much change in the American urological association symptoms index and the benign prostate hyperplasia impact index is perceptible to patients?","volume":"154","author":"Barry","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032795","article-title":"Determining the minimal important differences in the International Prostate Symptom Score and overactive bladder questionnaire: results from an observational cohort study in Dutch primary care","volume":"9","author":"Blanker","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0012","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT_PC randomized, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0013","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomized, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0014","unstructured":"Stereotactic body radiation therapy or intensity-modulated radiation therapy in treating patients with Stage IIA-B prostate cancer. ClinicalTrials.gov identifier NCT03367702. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03367702. Accessed May 4, 2022."},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0015","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ijrobp.2008.05.022","article-title":"Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: Long term outcome in 712 consecutive patients","volume":"73","author":"Keyes","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.04.006_bib0016","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ijrobp.2004.03.044","article-title":"PSA failure and risk of death in prostate cancer patients treated with radiotherapy","volume":"60","author":"Kwan","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622003194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622003194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:01:12Z","timestamp":1759744872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301622003194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0360301622003194"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.04.006","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Toxicity of Ultrahypofractionation Compared With Moderate Hypofractionation in Prostate Cancer Treatment: A Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}